<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01854749</url>
  </required_header>
  <id_info>
    <org_study_id>S1- ESCC -CJH</org_study_id>
    <nct_id>NCT01854749</nct_id>
  </id_info>
  <brief_title>S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study</brief_title>
  <official_title>S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the efficacy and safety of S1 combined with cisplatin in treatment of
      recurrence/metastasis of ESCC
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>from the first cycle of treatment (day one) to two month after the last cycle</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>S1 combined with cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S1 combined with cisplatin</intervention_name>
    <arm_group_label>S1 combined with cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Joined the study voluntarily and signed informed consent form;

          -  Age 18-75

             .Presence of at least one index lesion measurable by CT scan or MRI

          -  recurrence/metastasis of Esophageal carcinoma or gastroesophageal cancer confirmed by
             pathology

          -  No radiotherapy, chemotherapy or other treatments prior to enrollment

          -  PS ECOG 0-1

          -  Life expectancy of more than 3 months

          -  ANC≥2×109/L，PLT≥100×109/L，Hb≥90g/L

               -  Cr≤1.0×UNL

               -  TBIL≤1.25×UNL； ALT/AST≤2.5×UNL，with hepatic metastases
                  ALT/AST≤5.0×UNL；AKP≤2.5×UNL

        Exclusion Criteria:

          -  there is radical cure of the cancer

               -  uncontrolled chronic diarrhea and esophageal obstruction

               -  Neurological or mental abnormalities Influence of cognitive ability include
                  central nervous system metastases

               -  Severe complication(s), e.g.,uncontrolled active infection,myocardial
                  infarction,hypertension,arrhythmia,stenocardia

               -  Patient who has metastasis except cured skin basal cell carcinoma and carcinoma
                  in situ of cervix

          -  accept other antitumor therapy •Female patients during their pregnant and lactation
             period, or patients without contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cancer hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2013</study_first_submitted>
  <study_first_submitted_qc>May 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2013</study_first_posted>
  <last_update_submitted>February 22, 2016</last_update_submitted>
  <last_update_submitted_qc>February 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Chang Jian Hua</investigator_full_name>
    <investigator_title>Deputy director of medical oncology</investigator_title>
  </responsible_party>
  <keyword>ESCC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

